LENZ

$3.50+14.75%visit website

LENZ Therapeutics, Inc.

Market Cap

$110M

Live price × SEC shares (Oct 28, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

0.76

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Sep 2026 · negative earnings

P/S (TTM)

8.9

TTM to Sep 2026 · revenue

P/B

0.6

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Revenue	1,588	1,901	5,486	3,384	12,359
Cost of revenue	418	1,076	280	454	2,228
Research & development	0.00	0.00	0.00	0.00	0.00
Selling, general & administrative	39,633	44,960	39,378	35,848	159,819
Operating income	(38,463)	(44,135)	(34,172)	(32,918)	(149,688)
Pretax income	(35,894)		(31,915)	(30,969)
Income tax	2.00		3.00	0.00
Net income	(35,896)	(41,488)	(31,918)	(30,969)	(140,271)
EPS (basic) ($)		(1.32)	(1.02)	(0.99)	(4.53)
EPS (diluted) ($)		(1.32)	(1.02)	(0.99)	(4.53)
Weighted avg. shares (basic)		31,353	31,374	31,420
Weighted avg. shares (diluted)		31,353	31,374	31,420

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Nov 3, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 22 more quarters, back to Jun 2020, with Tormere Pro.

Corporate Events (8-K)

1 filing in 12 months · 1 with priority itemsFull history →

Filed	Items	Filing
Oct 28, 2026 accepted 4:34 PM ET	2.02Earnings release2.05Restructuring costs5.02Officer / director change	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

56%

W/W +3.0pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

23.98x

Avg Daily Selling (90d)

30,208 sh/day

Baseline Daily Selling

0.0 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-10-29	2026-11-02	RA CAPITAL MANAGEMENT, L.P.	10% Owner	Sale	2.72M	$3.36	$9.13M	57.6K	View
2026-03-27	2026-03-30	George Jeffrey P.	Director	Purchase	5,592	$8.92	$50K	5,592	View
2026-03-27	2026-03-30	Schimmelpennink Evert B.	Director & President, CEO and Secretary	Purchase	28.1K	$8.95	$251K	77.3K	View
2026-03-27	2026-03-30	Chevallard Daniel R.	Chief Financial Officer	Purchase	7,500	$8.57	$64K	12.9K	View

Recent News

LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Split On VIZZ

Yahoo Finance · 2026-11-04

Form 4 LENZ Therapeutics Inc: Daniel R. Chevallard (CFO) For: 30 October

Investing.com Canada · 2026-11-04

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga · 2026-11-03

LENZ (LENZ) Q3 2026 Earnings Call Transcript

Yahoo Finance · 2026-11-02

LENZ Therapeutics (LENZ) Stock Rallies As Q3 Results Expose Cash Burn

Yahoo Finance · 2026-10-30

Sophia Bush Shares Update on Friendships With One Tree Hill's Hilarie Burton, Bethany Joy Lenz

E! News · 2026-10-29

Lenz reports 75% workforce cut, CEO shakeup alongside Q3 earnings update

Fierce Pharma · 2026-10-29

LENZ Therapeutics Q3 Earnings Call Highlights

Yahoo Finance · 2026-10-29

LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates

Yahoo Finance · 2026-10-28

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession

Yahoo Finance · 2026-10-28

LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

Yahoo Finance · 2026-10-22

LENZ Therapeutics (LENZ) Stock Fair Value Falls After Analysts Cut VIZZ Launch Expectations

Yahoo Finance · 2026-10-21

LENZ Therapeutics: Below Cash For A Reason (NASDAQ:LENZ)

Seeking Alpha · 2026-09-25

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript

Yahoo Finance · 2026-08-19

LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary

Yahoo Finance · 2026-08-12

Informational purposes only, not investment advice.

Date	Insider	Type	Shares	Value
2026-10-29	RA CAPITAL MANAGEMENT, L.P.	S	2,159,516	$7M
2026-10-29	RA CAPITAL MANAGEMENT, L.P.	S	451,998	$2M
2026-10-29	RA CAPITAL MANAGEMENT, L.P.	S	107,170	$360,091.2
2026-03-27	George Jeffrey P.	P	5,592	$49,890.15
2026-03-27	Schimmelpennink Evert B.	P	28,089	$251,410.59

LENZ

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

LENZ Therapeutics, Inc. (LENZ)

Reporting Insiders

Factor Profile

Corporate Events (8-K)